Pubmed:
Expression of , and long non‑coding RNAs in papillary thyroid cancer and its effects on clinicopathological features.

dc.contributor.authorIcduygu, Fadime Mutlu
dc.contributor.authorAkgun, Egemen
dc.contributor.authorSengul, Demet
dc.contributor.authorOzgoz, Asuman
dc.contributor.authorAlp, Ebru
dc.date.accessioned2023-04-06T23:25:50Z
dc.date.available2023-04-06T23:25:50Z
dc.date.issued2022-04-01T00:00:00Z
dc.description.abstractLong non‑coding RNAs (lncRNAs) are molecules that are >200 base pairs long and do not encode a protein. However, they perform important roles in regulating gene expression. Recent studies have revealed that the changes in the expressions of lncRNAs serve a role in the development and metastases of a number of types of cancer. A number of studies have been published on the association of SOX2 overlapping transcript (), differentiation antagonizing non‑protein coding RNA () and tissue differentiation‑induced non‑coding RNA () expression with various types of cancer. However, researchers have not yet studied their roles in papillary thyroid cancer or at least, those roles are not clarified. The aim of the present study was to investigate the expression and clinical significance of , and in papillary thyroid cancer (PTC). A total of 102 patients with PTC were included in the present study. Reverse transcription‑quantitative PCR method was used to determine the relative gene expression levels of lncRNAs and then the relationship between expressions of lncRNAs and clinical characteristics of the subjects was analyzed in detail. Expression levels of (P=0.016) and (P=0.017) increased in the tumor samples in contrast to the normal tissues. No significant difference was observed in the expression level of (P=0.298). In addition, expression was associated with micro carcinoma (P<0.001), tumor size (P=0.010) and primary tumor (P=0.006), while expression was associated with age (P=0.030) and micro carcinoma (P=0.004). The findings of the present study indicated that may contribute to the development of PTC while may contribute to both the development and progression of PTC.
dc.identifier.doi10.3892/mmr.2022.12636
dc.identifier.issn1791-3004
dc.identifier.pubmed35147200
dc.identifier.urihttps://hdl.handle.net/20.500.12597/3336
dc.language.isoen
dc.relation.ispartofMolecular medicine reports
dc.subjectSOX2 overlapping transcript
dc.subjectdifferentiation antagonizing non‑protein coding RNA
dc.subjectlong non‑coding RNA
dc.subjectpapillary thyroid cancer
dc.subjectreverse transcription‑quantitative PCR
dc.subjecttissue differentiation‑induced non‑coding RNA
dc.titleExpression of , and long non‑coding RNAs in papillary thyroid cancer and its effects on clinicopathological features.
dc.typeJournal Article
dspace.entity.typePubmed
oaire.citation.issue4
oaire.citation.volume25
relation.isPublicationOfPubmed3460ab6a-5d04-4d94-b5a1-fe0431661479
relation.isPublicationOfPubmed.latestForDiscovery3460ab6a-5d04-4d94-b5a1-fe0431661479

Files